🇺🇸 FDA
Patent

US 7989501

Treating renal cancer using a 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-benzaldehyde

granted A61KA61K31/145A61K31/15

Quick answer

US patent 7989501 (Treating renal cancer using a 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-benzaldehyde) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jul 28 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Aug 02 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 28 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61K, A61K31/145, A61K31/15, A61K31/245, A61K31/277